Figure 3.

Distribution of insurance payment and out-of-pocket (OOP) expense on total vs discarded weight-based antineoplastic drugs (N = 1970). A) Distribution of insurance payment on weight-based antineoplastic drugs was similar between patients in high-deductible (HD) and non-HD plans. B) Distribution of insurance payment on discarded weight-based antineoplastic drugs was similar between patients in HD and non-HD plans. C) Distribution of OOP expenses on weight-based antineoplastic drugs showed a higher proportion of patients with HD plans in higher-cost categories and a lower proportion of HD patients had no OOP expense. D) Distribution of OOP expenses on discarded weight-based antineoplastic drugs showed a higher proportion of patients with HD plans in higher-cost categories and a lower proportion of HD patients had no OOP expense. The cut point of each cost category corresponds to median, 75th, 90th, and 95th percentiles of the distribution of the full sample.